These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33183197)

  • 21. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
    Dowty ME; Lin J; Ryder TF; Wang W; Walker GS; Vaz A; Chan GL; Krishnaswami S; Prakash C
    Drug Metab Dispos; 2014 Apr; 42(4):759-73. PubMed ID: 24464803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
    Xin Y; Jin D; Eppler S; Damico-Beyer LA; Joshi A; Davis JD; Kaur S; Nijem I; Bothos J; Peterson A; Patel P; Bai S
    J Clin Pharmacol; 2013 Nov; 53(11):1103-11. PubMed ID: 23922054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
    Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
    Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer.
    Yang J; Pradhan RS; Rosen LS; Graham AM; Holen KD; Xiong H
    J Clin Pharm Ther; 2014 Dec; 39(6):680-4. PubMed ID: 25047139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Mechanism and clinical progress of molecular targeted cancer therapy].
    Hu HX; Wang XQ; Zhang H; Zhang Q
    Yao Xue Xue Bao; 2015 Oct; 50(10):1232-9. PubMed ID: 26837167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
    Szałek E; Karbownik A; Grabowski T; Sobańska K; Wolc A; Grześkowiak E
    Pharmacol Rep; 2013; 65(5):1383-90. PubMed ID: 24399735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib.
    Wang C; Ying L; Jin M; Zhang F; Shi D; Dai Y; Zhou Z
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):43-52. PubMed ID: 33170322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
    Skoglund K; Richter J; Olsson-Strömberg U; Bergquist J; Aluthgedara W; Ubhayasekera SJ; Vikingsson S; Svedberg A; Söderlund S; Sandstedt A; Johnsson A; Aagesen J; Alsenhed J; Hägg S; Peterson C; Lotfi K; Gréen H
    Ther Drug Monit; 2016 Apr; 38(2):230-8. PubMed ID: 26693810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy.
    Yin Y; Yuan X; Gao H; Yang Q
    Int J Pharm; 2020 Jan; 573():118785. PubMed ID: 31678384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
    Tlemsani C; Huillard O; Arrondeau J; Boudou-Rouquette P; Cessot A; Blanchet B; Thomas-Schoemann A; Coriat R; Durand JP; Giroux J; Alexandre J; Goldwasser F
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):785-94. PubMed ID: 25809423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
    Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
    Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP3A4-mediated pharmacokinetic interactions in cancer therapy.
    Tian D; Hu Z
    Curr Drug Metab; 2014; 15(8):808-17. PubMed ID: 25705904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.
    Wulkersdorfer B; Zeitlinger M; Schmid M
    Clin Pharmacokinet; 2016 Jan; 55(1):47-77. PubMed ID: 26201307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
    Machiels JP; Staddon A; Herremans C; Keung C; Bernard A; Phelps C; Khokhar NZ; Knoblauch R; Parekh TV; Dirix L; Sharma S
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):729-37. PubMed ID: 25100135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
    Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
    J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
    Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
    Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammation and altered drug clearance in cancer: transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice.
    Robertson GR; Liddle C; Clarke SJ
    Clin Pharmacol Ther; 2008 Jun; 83(6):894-7. PubMed ID: 18388870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Sonnichsen D
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.